Skip to main content
SpringerLink
Log in

What to do with non-responders

  • Conference paper
Portal Hypertension in the 21st Century

Abstract

Hemodynamic monitoring provides an accurate stratification of bleeding risk and may enable tailoring of therapy1. This may be particularly useful in the prevention of rebleeding, when the risk is much higher than in primary prevention2.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol. 2003;38:S54–68.

    Article  Google Scholar 

  2. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology. 2001;120:726–48.

    Article  PubMed  CAS  Google Scholar 

  3. Groszmann RJ, Bosch J, Grace ND et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology. 1990;99:1401–7.

    PubMed  CAS  Google Scholar 

  4. Feu F, Garcia-Pagan JC, Bosch J et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet. 1995;346:1056–9.

    Article  PubMed  CAS  Google Scholar 

  5. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology. 1985;5:419–24.

    Article  PubMed  CAS  Google Scholar 

  6. Vorobioff J, Groszmann RJ, Picabea E et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology. 1996;111:701–9.

    Article  PubMed  CAS  Google Scholar 

  7. Villanueva C, Balanzó J, Novella M et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med. 1996;334:1624–9.

    Article  PubMed  CAS  Google Scholar 

  8. Villanueva C, Minana J, Ortiz J et al. Endoscopic ligation compared with combined treatment with nadolol plus isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med. 2001;345:647–55.

    Article  PubMed  CAS  Google Scholar 

  9. Merkel C, Bolognesi M, Sacerdoti D et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology. 2000;32:930–4.

    Article  PubMed  CAS  Google Scholar 

  10. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodés J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37:902–8.

    Article  PubMed  Google Scholar 

  11. Villanueva C, López-Balaguer JM, Aracil C et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol. 2004;40:757–65.

    Article  PubMed  Google Scholar 

  12. Boyer TD. Pharmacologic treatment of portal hypertension: past, present and future. Hepatology. 2001;34:834–9.

    Article  PubMed  CAS  Google Scholar 

  13. Kroeger RJ, Groszmann RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agnets in a portal hypertensive model. Hepatology. 1985;5:97–101.

    Article  PubMed  CAS  Google Scholar 

  14. Garcia-Pagan JC, Feu F, Bosch J, Rodés J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med. 1991;114:869–73.

    PubMed  CAS  Google Scholar 

  15. Merkel C, Sacerdoti D, Bolognesi M et al. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the b-blocker alone. Hepatology. 1997;26:34–9.

    PubMed  CAS  Google Scholar 

  16. De Franchis R. Updating consensus in portal hypertension: report ofthe Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepalol. 2000;33:846–52.

    Article  Google Scholar 

  17. Groszmann RJ, Garcia-Tsao G. Endoscopic variceal ligation vs. pharmacological therapy for the prevention of recurrent variceal hemorrhage: What makes the difference? Gastroenterology. 2002;123:1388–91.

    Article  PubMed  Google Scholar 

  18. D’Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis. 1999;19:475–505.

    Article  PubMed  Google Scholar 

  19. García-Pagán JC, Villanueva C, Vila MC et al. and Members of the MOVE group. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive b-blockers. Gastroenterology. 2001;121:908–14.

    Article  PubMed  Google Scholar 

  20. Garcia-Tsao G, Grace ND, Groszmann RJ et al. Short-term effects of propranolol on portal pressure. Hepatology. 1986;6:101–6.

    Article  PubMed  CAS  Google Scholar 

  21. Vorobioff J, Picabea E, Villavicencio R et al. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology. 1987;7:648–53.

    Article  PubMed  CAS  Google Scholar 

  22. Escorsell A, Bordas JM, Castañeda B et al. Predictive value of variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology. 2000;31:1061–7.

    Article  PubMed  CAS  Google Scholar 

  23. Feu F, Bordas JM, Luca A et al. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. Hepatology. 1993;18:1082–9.

    PubMed  CAS  Google Scholar 

  24. Garcia-Pagan JC, Navasa M, Bosch J, Bru C, Pizcueta P, Rodés J. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitratc to propranolol administration in patients with cirrhosis. Hepatology. 1990;11:230–8.

    Article  PubMed  CAS  Google Scholar 

  25. Albillos A, García-Pagán JC, Iborra J et al. Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology. 1998;115:116–23.

    Article  PubMed  CAS  Google Scholar 

  26. Morillas R, Planas R, Cabré E et al. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects. Hepatology. 1994;20:1502–8.

    Article  PubMed  CAS  Google Scholar 

  27. Merkel C, Gatta A, Donada C et al. Long-term effects of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. Hepatology. 1995;22:808–13.

    PubMed  CAS  Google Scholar 

  28. Gournay J, Masliah C, Martin T, Perrin D, Galmiche JP. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology. 2000;31:1239–45.

    Article  PubMed  CAS  Google Scholar 

  29. Patti R, D’Amico G, Pasta L et al. Isosorbide mononitrate (IMN) with nadolol compared with nadolol alone for the prevention of recurrent bleeding in cirrhosis. A double-blind placebo-controlled randomized trial. J Hepatol. 1999;30:81 (abstract).

    Google Scholar 

  30. Patch D, Sabin CA, Goulis J et al. A randomized controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology. 2002;123:1013–19.

    Article  PubMed  CAS  Google Scholar 

  31. Lo GH, Chen WC, Chen MH et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal bleeding. Gastroenterology. 2002;123:728–34.

    Article  PubMed  Google Scholar 

  32. McCormick PA, Feu F, Sabrin C, Planas R and the Anglo-Spanish variceal rebleeding group. Propranolol and isosorbide mononitrate versus sclerotherapy or shunt surgery for the prevention of variceal rebleeding: a randomized trial. Hepatology. 1994;20:106A (abstract).

    Article  Google Scholar 

  33. Bureau C, Péron JM, Alric L et al. „A la carte“ treatment of portal hypertension: adapting therapy to hemodynamic response for the prevention of bleeding. Hepatology. 202;36:1361–6.

    Google Scholar 

  34. Thalheimer U, Mela M, Patch D, Burroughs AK. Targeting portal pressure measurements: a critical reappraisal. Hepatology. 2004;39:286–90.

    Article  PubMed  Google Scholar 

  35. Burroughs AK, D’Heygere F, McIntyre N. Pitfalls in studies of prophylactic therapy for variceal bleeding in cirrhosis. Hepatology. 1986;6:1407–13.

    Article  PubMed  CAS  Google Scholar 

  36. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology. 1999;29:334–9.

    Article  PubMed  CAS  Google Scholar 

  37. Schepke M, Werner E, Bieker E et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology. 2001;121:389–95.

    Article  PubMed  CAS  Google Scholar 

  38. González-Abraldes J, Albillos A, Bañares R et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology. 2001;121:382–8.

    Article  PubMed  Google Scholar 

  39. Debernardi-Venon W, Baronio M, Leone N et al. Effects of irbesartan in reducing portal pressure in cirrhotic patients: comparison with propranolol in a randomised controlled trial. J Hepatol. 2003;38:455–60.

    Article  Google Scholar 

  40. Okumura H, Aramaki T, Katsuta Y et al. Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol. 1991;86:46–52.

    PubMed  CAS  Google Scholar 

  41. García-Pagán JC, Salmeron JM, Feu F et al. Effects oflow-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology. 1994;19:1095–9.

    Article  PubMed  Google Scholar 

  42. Nevens F, Lijnen P, VanBilioen H, Fevery J. The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. Hepatology. 1996;23:1047–52.

    Article  PubMed  CAS  Google Scholar 

  43. Abecasis R, Kravetz D, Fassio E et al. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: a preliminary study. Hepatology. 2003;37:359–65.

    Article  PubMed  CAS  Google Scholar 

  44. Bañares R, Moitinho E, Piqueras B et al. Carvediol, a new nonselective beta-blocker with intrinsic anti-α-1-adrenergic activity, has greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology. 1999;30:79–83.

    Article  PubMed  Google Scholar 

  45. Bañares R, Moitinho E, Matilla A et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology. 2002;36:1367–73.

    PubMed  Google Scholar 

  46. Stanley A, Therapondos G, Helmy A, Hayes PC. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. J Hepatol. 1999;30:479–84.

    Article  PubMed  CAS  Google Scholar 

  47. Tripathi D, Therapondos G, Helmy A, Hayes PC. Haemodynamic effects of acute and chronic administration of long-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. Aliment Pharmacol Ther. 2002;16:373–80.

    Article  PubMed  CAS  Google Scholar 

  48. Wiest R, Gorszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology. 2002;35:478–91.

    Article  PubMed  CAS  Google Scholar 

  49. Albillos A, Lledó JL, Rossi I et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology. 1995;109:1257–65.

    Article  PubMed  CAS  Google Scholar 

  50. Bosch J. Decreasing hepatic vascular tone by liver-specific NO donors: wishful thinking or a promising reality? J Hepatol. 2003;39:1072–5.

    Article  PubMed  CAS  Google Scholar 

  51. Lee S, Hadengue A, Moreau R, Sayegh R, Hillon P, Lebrec D. Postprandial hemodynamic responses in patients with cirrhosis. Hepatology. 1988;8:647–51.

    Article  PubMed  CAS  Google Scholar 

  52. McCormick PA, Dick R, Graffeo M et al. The effect of non-protein liquid meals on the hepatic venous pressure gradient in patients with cirrhosis. J Hepatol. 1990;11:221–5.

    Article  PubMed  CAS  Google Scholar 

  53. Polio J, Groszmann RJ. Hemodynamic factors involved in the development and rupture of esophageal varices: a pathophysiologic approach to treatment. Semin Liver Dis. 1986; 6:318–31.

    Article  PubMed  CAS  Google Scholar 

  54. McCormick PA, Jenkins SA, McIntyre N, Burroughs AK. Why portal hypertensive varices bleed and bleed: a hypothesis. Gut. 1995;36:100–3.

    Article  PubMed  CAS  Google Scholar 

  55. García-Pagan JC, Santos C, Barberá JA et al. Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. Gastroenterology. 1996;111:1300–6.

    Article  PubMed  Google Scholar 

  56. Luca A, Cirera I, Garcia-Pagán JC et al. Hemodynamic effects of acute changes in intraabdominal pressure in patients with cirrhosis. Gastroenterology. 1993;104:222–7.

    PubMed  CAS  Google Scholar 

  57. Bellis L, Berzigotti A, Abraldes JG et al. Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology. 2003; 37:378–84.

    Article  PubMed  CAS  Google Scholar 

  58. Villanueva C, Ortiz J, Miñana J et al. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology. 2001;121:110–17.

    Article  PubMed  CAS  Google Scholar 

  59. Zafra C, Abraldes JG, Cortez C et al. Simvastatin ameliorates the increased hepatic vascular tone in patients with cirrhosis. J Hepatol. 2003;38(Suppl. 12):12.

    Article  Google Scholar 

  60. Aracil C, López-Balaguer JM, Monfort D et al. Hemodynamic response to beta-blockers and prediction of clinical efficacy in the primary prophylaxis of variceal bleeding in patients with cirrhosis. Hepatology. 2003;38:296A (abstract).

    Article  Google Scholar 

  61. Korula J, Ralls P. The effects of chronic endoscopic variceal sclerotherapy on portal pressure in cirrhotics. Gastroenterology. 1991;101:800–5.

    PubMed  CAS  Google Scholar 

  62. Lo GH, Liang HL, Lai KH et al. The impact of endoscopic variceal ligation on the pressure of the portal venous system. J Hepatol. 1996;24:74–8.

    Article  PubMed  CAS  Google Scholar 

  63. De Franchis R, Primignani M. Endoscopic treatments for portal hypertension. Semin Liver Dis. 1999;19:439–55.

    Article  PubMed  Google Scholar 

  64. Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med. 1995;123:280–7.

    PubMed  CAS  Google Scholar 

  65. Burroughs AK, Patch D. Transjugular intrahepatic portosystemic shunt. Semin Liver Dis. 1999;19:457–73.

    Article  PubMed  CAS  Google Scholar 

  66. Escorsell A, Bañares R, García-Pagan JC et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology. 2002;35:385–92.

    Article  PubMed  Google Scholar 

  67. Papatheodoridis GV, Goulis J, Leandro G, Patch D, Burroughs AK. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: a meta-analysis. Hepatology. 1999;30:612–22.

    Article  PubMed  CAS  Google Scholar 

  68. Adam R, Cailliez V, Majno P et al. Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry Group. Lancet. 2000;356:621–7.

    Article  PubMed  CAS  Google Scholar 

  69. Ready JB, Robertson AD, Goff JS, Rector WG. Assessment of the risk of bleeding from esophageal varices by continuous monitoring of portal pressure. Gastroenterology. 1991;100:1403–10.

    PubMed  CAS  Google Scholar 

  70. Moitinho E, Escorsell A, Bandi JC et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology. 1999;117:626–31.

    Article  PubMed  CAS  Google Scholar 

  71. Monescillo A, Martinez-Lagares F, Sierra A et al. Treatment of acute variceal bleeding by the hepatic venous pressure gradient: preliminary results of a randomized trial. Hepatology. 1999;30:220A (abstract).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servei de Patologia Digestiva, Hospital de la Santa Creu I Sant Pau, Avgda. Sant Antoni Ma. Claret, 167, 08025, Barcelona, Spain

    Càndid Villanueva

Authors
  1. Càndid Villanueva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carles Aracil
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joaquim Balanzó
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Yale University School of Medicine, New Haven, CT, USA

    R. J. Groszmann

  2. Hepatic Hemodynamic Laboratory Liver Unit, Hospital Clinic, University of Barcelona, Spain

    J. Bosch

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media Dordrecht

About this paper

Cite this paper

Villanueva, C., Aracil, C., Balanzó, J. (2004). What to do with non-responders. In: Groszmann, R.J., Bosch, J. (eds) Portal Hypertension in the 21st Century. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-1042-9_34

Download citation

  • DOI: https://doi.org/10.1007/978-94-007-1042-9_34

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-3774-7

  • Online ISBN: 978-94-007-1042-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation